PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): Influence on patients' diagnostic and therapeutic management

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 1, 2003, Pages 47-58

  Mantaka, Panagiota ^a,c   Baum, Richard P ^b   Hertel, Andreas ^a   Adams, Stefan ^a   Niessen, Andreas ^b   Sengupta, Sonali ^a   Hör, Gustav ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Central Clinic Bad Berka   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

2 F 18 fluoro deoxy D glucose (FDG); Cancer of unknown primary (CUP); Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER OF UNKNOWN PRIMARY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

EID: 0037219490     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803321269322     Document Type: Article

References (36)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: Cancer: Principles of Oncology, 4th edition, Devita VT Jr, Hellman S, Rosenberg SA (ed), Philadelphia, 1993, 2072-2092.
2. Daugaard G. Unknown primary tumours. Cancer Treat Rev; 20(2):119-147 (1994).
3. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol; 13:2094-2103 (1995).
4. Abbruzzese JL, Raber MN: Part III. Management of specific malignancies: Unknown Primary, Clinical Oncology, 4th edition, Martin D. Abeloff, James O. Armitage, Allen S. Lichter and John E. Niederhuber, 1995, 1833-1845.
5. nd edition, Million RR, Cassisi NJ (ed), Philadelphia, 1994, 311-320.
6. Atula TS, Varpula MJ, Kurki TJ, Klemi P-J, Grénman R. Assessment of cervical lymph node status in head and neck cancer patients: palpation, computed tomography and low field magnetic resonance imaging compared with ultrasound-guided fine-needle aspiration cytology. Eur J Radiol; 25(2):152-161 (1997).
7. Strauss LG, Conti PS. The applications of PET in Clinical Oncology. J Nucl Med; 32:623-648 (1991).
8. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DHS, Czernin J, Maddahi J, Phelps ME. PET in oncology: will it replace the other modalities? Semin Nucl Med; 27(2):94-106 (1997).
9. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med Biol; 21(5):739-747 (1994).
10. Hör G, Adams S, Baum RP, Hertel A, Adamietz IA, Böttcher HD, Kollath J. Impact of single photon emission computed tomography and positron emission tomography on diagnostic oncology. Diagn Oncol; 4:297-321 (1997).
11. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med; 23:1641-1677 (1996).
12. Strauss LG. Positron emission tomography: current role for diagnosis and therapy monitoring in oncology. The Oncologist; 2:381-388 (1997).
13. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer; 82(9):1664-1671 (1998).
14. Stuckensen T, Kovacs, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Maxillofac Surg; 28(6):319-324 (2000).
15. Mantaka P, Strauss AD, Strauss LG, Moehler M, Goldschmidt H, Oberdorfer F, Kontaxakis G, van Kaick G. Detection of treated liver metastases using fluorine-18-fluorodeoxyglucose (FDG) and positron emission tomography (PET). Anticancer Res; 19(5c):4443-4450 (1999).
16. Rege S, Maass A, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y, Juillard G, Maddahi J, Phelps ME. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer; 73:3047-3058 (1994).
17. Krulik M. Metastatic cancers of unknown primary site. Presse Med; 25(35):1754-1758 (1996).
18. Pavlidis N, Kalef-Ezra J, Briassoulis E, Skarlos D, Kosmidis P, Saferiadis K, Bairaktari E, Bafaloukos D, Maravegias A, Theoharis D et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol; 22(3):162-167 (1994).
19. Chevalier TL, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, Rouesse J. Early metastatic cancer of unknown primary origin at presentation. Arch Intern Med; 148:2035-2039 (1988).
20. Nystrom JS, Wiener JM, Wolf RM, Bateman JR, Viola MV. Identifying the primary site in metastatic cancer of unknown origin: Inadequacy of roentgenographic procedures. JAMA; 241:381-383 (1979).
21. McMillan JH, Levine L, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. Radiology; 143:143-146 (1982).
22. Karsell PR, Sheedy PF, O'Connel MJ. Computed tomography in search of cancer of unknown origin. JAMA; 248:340-343 (1982).
23. Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW. Characterisation of chest masses by FDG Positron Emission Tomography. Clin Nucl Med; 20(4):293-298 (1995).
24. Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest; 114(4):1105-1111 (1998).
25. Crowe JP Jr, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol; 1(2):132-140 (1994).
26. Adler LP, Crowe JP, al Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (F-18)-2-deoxy-2-fluoro-D-glucose PET. Radiology; 187:743-750 (1993).
27. Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Göhring U-J, Schomäcker K, Schicha H. Qualitative [F-18] FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med; 23:618-623 (1996).
28. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med; 23:1409-1415 (1996).
29. Kontaxakis G, Strauss LG, Tzanakos GS. An efficient implementation of the iterative ML-EM image reconstruction algorithm for PET on a Pentium PC platform. Journal of Computing and Information Technology-CIT; 7:153-163 (1999).
30. Greven KM, Keyes Jr. JW, Williams III DW, McGuirt WF, Joyce III WT. Occult primary tumors of the head and neck. Lack of benefit from Positron Emission Tomography Imaging with 2-[F-18]Fluoro-2-Deoxy-D-Glucose. Cancer; 86:114-178 (1999).
31. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18F-FDG Whole Body Positron Emission Tomography (PET) in Patients with Unknown Primary Tumors (UPT). Eur J Cancer; 35(7):1076-1082 (1999).
32. Aassar OS, Fischbein NJ, Caputo GR, Kaplan MJ, Price DC, Singer MI, Dillon WP, Hawkins RA. Metastatic Head and Neck Cancer: Role and Usefulness of FDG PET in Locating Occult Primary Tumors. Radiology; 210:177-181 (1999).
33. Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Schraffordt Koops H, Roodenburg JLN, Vaalburg W, Vermey A. Detection of Unknown Primary Tumors Using Positron Emission Tomography. Cancer; 82:1160-1166 (1998).
34. Lonneux M, Reffad A. Metastases from Unknown Primary Tumor. PET-FDG as Initial Diagnostic Procedure? Clin Positron Imaging; 3(4):137-141 (2000).
35. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java enviroment for medical image data analysis: initial application for brain PET quantitation. Med Inform; 23:207-214 (1998).
36. Toorongian SA, Mulholland GK, Jewett DM, Bachelor MA, Kilbourn MR. Routine production of 2-deoxy-2(18F)fluoro-D-glucose by directed nucleophilic exchange on a quaternary 4-aminopyridinium resin. Int J Rad Appl Instrum B; 17(3):273-279 (1990).